State Street Corp Acurx Pharmaceuticals, Inc. Call Options Transaction History
State Street Corp
- $2.21 Trillion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ACXP
# of Institutions
30Shares Held
1.25MCall Options Held
16.1KPut Options Held
33.8K-
Vanguard Group Inc Valley Forge, PA492KShares$1.11 Million0.0% of portfolio
-
Prospect Financial Services LLC Melville, NY273KShares$613,9120.55% of portfolio
-
Geode Capital Management, LLC Boston, MA116KShares$261,7920.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ57.3KShares$128,8120.0% of portfolio
-
Lpl Financial LLC Fort Mill, SC40.2KShares$90,5280.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $26M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...